Serpin Pharma, Inc. Press Releases

• Published on October 7, 2024 - 14:07 GMT

  

  Serpin Pharma Secures $2 Million NCI Grant for Innovative Neuropathy Treatment

  MANASSAS, VA, UNITED STATES, October 7, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a Virginia-based biopharmaceutical company, is proud to announce that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on September 17, 2024 - 15:21 GMT

  

  Serpin Pharma and Uniklinikum Erlangen Team Up for a Clinical Trial to Prevent Acute Kidney Injury

  MANASSAS, VA, UNITED STATES, September 17, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a leading clinical-stage pharmaceutical company, is thrilled to announce its partnership with Uniklinikum Erlangen in Germany for a groundbreaking clinical trial focused …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on July 8, 2024 - 17:26 GMT

  

  Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

  Serpin Pharma and HekaBio have signed a term sheet to develop and commercialize SP163M for preventing chemotherapy-induced peripheral neuropathy (CIPN). MANASSAS, VIRGINIA, UNITED STATES, July 8, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a Virginia- …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on February 15, 2024 - 20:43 GMT

  Serpin Pharma Files U.S. Patent Application for SP16 - mRNA for Extended-Release in Injured Tissues

  MANASSAS, VIRGINIA, UNITED STATES, February 15, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a pioneering clinical-stage pharmaceutical company specializing in the treatment of inflammation, has announced the filing of a U.S. patent application for the “ …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on February 1, 2024 - 17:23 GMT

  Sanofi's $2.2B AAT Acquisition Highlights Need for New Treatments Like Serpin Pharma’s SP16, a AAT Bio superior

  MANASSAS, VIRGINIA, UNITED STATES, February 1, 2024 /⁨EINPresswire.com⁩/ -- Sanofi’s recent acquisition of a recombinant alpha-1 antitrypsin (AAT) drug candidate for $2.2 billion highlights the critical need for innovative solutions in addressing the …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on January 26, 2024 - 15:20 GMT

  Serpin Pharma Secures $900,000 BIRD Foundation Grant for Clinical Trial in AMI Treatment

  MANASSAS, VIRGINIA, UNITED STATES, January 26, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a pioneering clinical-stage pharmaceutical company headquartered in Virginia, has been awarded a competitive $900,000 grant by the Bi-national Industrial Research …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on January 12, 2024 - 18:45 GMT

  Serpin Pharma Welcomes Dr. Alexander Fleming to its Board of Directors

  MANASSAS, VIRGINIA, UNITED STATES, January 12, 2024 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a leading biopharmaceutical company dedicated to development anti-inflammatory and immune-modulating drugs to treat human diseases caused by inflammation, proudly …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on September 22, 2022 - 17:56 GMT

  

  Serpin Pharma completes Phase 1b/2a SPIRIT Clinical Trial

  MANASSAS, VIRGINIA, UNITED STATES, September 22, 2022 /⁨EINPresswire.com⁩/ -- Serpin Pharma, a clinical-stage biotech company developing first in class drugs to treat human diseases caused by inflammation, reported data from its Phase 1b/2a clinical trial. …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...